Predicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
PSA testing from 2002 to 2006
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[PRIMARY FUNDING SOURCE] None.
[BACKGROUND] Despite the scale of prostate-specific antigen (PSA) testing for prostate cancer (PCa) screening, prediction models do not predict time-to-event end points or adjust for patient life expe
APA
Lewicki P, Jiang R, et al. (2026). Predicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation.. Annals of internal medicine, 179(3), 321-329. https://doi.org/10.7326/ANNALS-25-02036
MLA
Lewicki P, et al.. "Predicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation.." Annals of internal medicine, vol. 179, no. 3, 2026, pp. 321-329.
PMID
41525694 ↗
Abstract 한글 요약
[BACKGROUND] Despite the scale of prostate-specific antigen (PSA) testing for prostate cancer (PCa) screening, prediction models do not predict time-to-event end points or adjust for patient life expectancy.
[OBJECTIVE] To develop, externally validate, and compare to existing tools a novel prognostic model for risk for prostate cancer-specific mortality (PCSM) after a PSA test.
[DESIGN] Prognostic model development in the PCa screening group of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial; external validation in a Veterans Affairs (VA) population of patients undergoing PSA testing.
[SETTING] United States. PLCO patients were enrolled from 1993 to 2001, and VA patients underwent PSA testing from 2002 to 2006. Survival follow-up was updated through 2022 in both cohorts.
[PATIENTS] Male patients aged 55 to 74 years in the PLCO PCa screening group ( = 33 339) and the VA Healthcare System ( = 174 787).
[MEASUREMENTS] The model's predicted outcome is PCSM at a specified time point; predictors included PSA level, family history of PCa, and race. Predictors of other-cause mortality included age; body mass index; smoking status; and presence of hypertension, diabetes, or stroke.
[RESULTS] In the model development cohort, the area under the receiver operating characteristic curve (AUC) at 29.5 years from screening was 0.666 compared with 0.643 for a previously validated prostate biopsy risk model (Prostate Biopsy Collaborative Group [PBCG]) ( < 0.001). In the external validation cohort, the AUC at 20 years from screening was 0.776 for the PLCO model versus 0.749 for the PBCG model ( = 0.031).
[LIMITATION] The model may not be generalizable to more contemporary PSA screening practices given the periods studied.
[CONCLUSION] This PCSM prognostic model was developed from long-term clinical trial data, was externally validated in a large national cohort, and may be used to improve interpretation of PSA results.
[PRIMARY FUNDING SOURCE] None.
[OBJECTIVE] To develop, externally validate, and compare to existing tools a novel prognostic model for risk for prostate cancer-specific mortality (PCSM) after a PSA test.
[DESIGN] Prognostic model development in the PCa screening group of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial; external validation in a Veterans Affairs (VA) population of patients undergoing PSA testing.
[SETTING] United States. PLCO patients were enrolled from 1993 to 2001, and VA patients underwent PSA testing from 2002 to 2006. Survival follow-up was updated through 2022 in both cohorts.
[PATIENTS] Male patients aged 55 to 74 years in the PLCO PCa screening group ( = 33 339) and the VA Healthcare System ( = 174 787).
[MEASUREMENTS] The model's predicted outcome is PCSM at a specified time point; predictors included PSA level, family history of PCa, and race. Predictors of other-cause mortality included age; body mass index; smoking status; and presence of hypertension, diabetes, or stroke.
[RESULTS] In the model development cohort, the area under the receiver operating characteristic curve (AUC) at 29.5 years from screening was 0.666 compared with 0.643 for a previously validated prostate biopsy risk model (Prostate Biopsy Collaborative Group [PBCG]) ( < 0.001). In the external validation cohort, the AUC at 20 years from screening was 0.776 for the PLCO model versus 0.749 for the PBCG model ( = 0.031).
[LIMITATION] The model may not be generalizable to more contemporary PSA screening practices given the periods studied.
[CONCLUSION] This PCSM prognostic model was developed from long-term clinical trial data, was externally validated in a large national cohort, and may be used to improve interpretation of PSA results.
[PRIMARY FUNDING SOURCE] None.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (4)
- Real-world experience with PSMA-PET in primary staging and biochemical recurrence settings: data from the Michigan Urological Surgery Improvement Collaborative.
- Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial.
- Abnormal Flagging of Prostate Specific Antigen Screening Tests: A Regression Discontinuity Design.
- What is lost in an average? Identifying distinct post-radical prostatectomy functional recovery profiles.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.